DEL-1 and Thromboxane A2 in Diabetic Nephropathy Patients

Diabetic nephropathy is one of the most common microvascular complications of diabetes mellitus and a leading cause of chronic kidney disease. Inflammation and platelet activation are believed to play a significant role in its pathogenesis and progression.

Developmental endothelial locus-1 (DEL-1) is an anti-inflammatory protein that regulates leukocyte adhesion and endothelial function, while thromboxane A2 is a marker of platelet activation and contributes to vascular dysfunction.

This study aims to evaluate serum levels of DEL-1 and thromboxane A2, and their relationship with platelet count in patients with diabetic nephropathy. Additionally, the study investigates the correlation between these biomarkers and disease severity.

This observational cross-sectional study will be conducted on 80 participants, including patients with diabetic nephropathy and healthy controls, to explore the potential role of these biomarkers in disease progression and their possible use as diagnostic or prognostic indicators.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Nephropathy, Diabetic Diabetes Complications Diabetes Mellitus Diabetic Nephropathies Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Urogenital Diseases Urologic Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patients aged between 18 and 70 years.
Patients diagnosed with diabetic nephropathy based on clinical and laboratory findings.
Patients undergoing evaluation or follow-up for diabetic kidney disease.
Ability and willingness to provide informed consent.

Exclusion criteria

- Patients with known hepatic disease.
Patients with significant cardiovascular disease.
Patients with malignancy.
Patients who have undergone recent surgery.
Patients with known hematological disorders or hypercoagulable states.
Patients receiving medications that significantly affect platelet function.

Treatment and study plan

No intervention

Other

No intervention is applied. This is an observational study involving clinical assessment and blood sample collection for laboratory analysis only.

Primary outcomes

Serum level of Developmental Endothelial Locus-1 (DEL-1). Time Frame: Baseline

Time frame: Baseline

Measurement of serum DEL-1 levels in patients with diabetic nephropathy compared with healthy controls.

Sponsors and collaborators

Lead sponsor

Aswan University

Other

Registry information

Official study title

Developmental Endothelial Locus-1 Serum Level and Its Relation With Thromboxane A2 and Platelet Count in Patients With Diabetic Nephropathy

Acronym: DEL1-DN

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2027
First posted: Aug 6, 2026
Registry last updated: Aug 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed